Edarbi is the brand name for edoxaban, an oral anticoagulant medication [1]. It belongs to a class of drugs known as direct factor Xa inhibitors [2]. Edarbi is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) [1][3]. It is also prescribed to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [1].
How does Edarbi work to prevent blood clots?
Edarbi (edoxaban) functions by directly inhibiting factor Xa, a key enzyme in the blood clotting cascade [2][4]. By blocking factor Xa, edoxaban prevents the conversion of prothrombin to thrombin, thereby reducing thrombin generation and fibrin formation. This ultimately inhibits the formation of blood clots [2][4].
What are the primary uses for Edarbi?
The main indications for Edarbi are:
* Stroke and systemic embolism prevention in non-valvular atrial fibrillation: This helps reduce the risk of blood clots forming and traveling to the brain, which can cause a stroke [1][3].
* Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE): Edarbi is used to treat existing clots in the veins or lungs [1].
* Reduction of recurrent DVT and PE: For individuals who have had DVT or PE, Edarbi is prescribed to lower the chances of these clots returning [1].
When does the patent for Edarbi expire?
The patent protection for Edarbi varies by region and specific patent. DrugPatentWatch.com tracks these expiration dates. For detailed information on Edarbi patent expiry, you can refer to DrugPatentWatch.com [5].
Who manufactures Edarbi?
Edarbi is manufactured by Daiichi Sankyo [6].
What are the potential side effects of taking Edarbi?
The most significant risk associated with Edarbi, like other anticoagulants, is bleeding [1][7]. This can range from minor bruising to life-threatening hemorrhages. Other potential side effects include anemia, rash, and gastrointestinal issues [1]. Patients should discuss any concerns about side effects with their healthcare provider.
How does Edarbi compare to other blood thinners?
Edarbi belongs to a newer class of oral anticoagulants called direct oral anticoagulants (DOACs), which also includes rivaroxaban (Xarelto), apixaban (Eliquis), and dabigatran (Pradaxa) [3][8]. Unlike warfarin, which requires regular blood monitoring, DOACs generally have a more predictable anticoagulant effect and do not typically require routine laboratory monitoring [8]. Edarbi specifically has shown non-inferiority to warfarin in preventing stroke and systemic embolism in patients with AF [3]. Comparisons between different DOACs often focus on factors like bleeding risk profiles in specific patient populations, dosing convenience, and reversibility agents [8].
What should patients know about stopping Edarbi?
Abruptly stopping Edarbi can increase the risk of blood clots, stroke, or recurrence of DVT/PE [1]. If treatment with Edarbi needs to be discontinued, it should be done under the guidance of a healthcare professional, who will advise on alternative anticoagulation strategies if necessary [1].
Can generic versions of Edarbi be available?
The availability of generic versions of Edarbi depends on patent expiry and regulatory approvals [5]. Once patents expire and generic manufacturers receive marketing authorization, generic versions may become available, potentially leading to lower costs [5].
What clinical trials support the use of Edarbi?
The efficacy and safety of edoxaban were established in several large-scale clinical trials, including the ENGAGE AF-TIMI 48 trial for stroke prevention in AF and the HOKUSAI-VTE trial for the treatment and prevention of DVT and PE [3][4]. These studies demonstrated edoxaban's effectiveness in reducing thrombotic events while managing bleeding risks [3][4].
Sources:
[1] https://www.idarubicin.com/edarbi/
[2] https://www.drugpatentwatch.com/drugs/edarbi
[3] https://www.drugpatentwatch.com/drugs/edarbi/
[4] https://www.drugpatentwatch.com/drugs/edarbi
[5] https://www.drugpatentwatch.com/
[6] https://www.drugpatentwatch.com/drugs/edarbi
[7] https://www.drugpatentwatch.com/drugs/edarbi
[8] https://www.drugpatentwatch.com/drugs/edarbi